Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.

Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.

Swiss-based Rejuveron’s diversified platform of longevity biotechs addresses key hallmarks of aging, with the goal of helping people to age better and live longer with reduced burden of age-related diseases. CEO Matthias Steger discusses the firm’s vision and the road ahead.

ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.